共 50 条
Pragmatic randomized clinical trials: a proposal to enhance evaluation of new cancer therapies with early signs of exceptional activity
被引:12
|作者:
Koehler, M.
[1
]
Donnelly, E. T.
[2
]
Kalanovic, D.
[3
]
Dagher, R.
[4
]
Rothenberg, M. L.
[1
]
机构:
[1] Pfizer Oncol, New York, NY 10017 USA
[2] Pfizer Oncol, Cambridge, MA USA
[3] Pfizer Oncol, Reg Med Affairs, Berlin, Germany
[4] Pfizer, Worldwide Safety & Regulatory, Groton, CT USA
关键词:
WORLD EFFECTIVENESS TRIAL;
MULTIPLE-MYELOMA;
DRUG DEVELOPMENT;
SALFORD LUNG;
BORTEZOMIB;
PROTOCOL;
AGE;
D O I:
10.1093/annonc/mdw143
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
We propose that for oncology drugs that demonstrate "exceptional activity" in Phase 1 or Phase 2 trials and receive accelerated/conditional approval and/or Breakthrough Therapy Designation, and for certain expanded indications, regulatory authorities should consider accepting data from prospectively-agreed pragmatic randomized clinical trials to grant full regulatory approval.
引用
收藏
页码:1342 / 1348
页数:7
相关论文